Actively Recruiting
Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog
Led by Xuanwu Hospital, Beijing · Updated on 2025-09-04
40
Participants Needed
2
Research Sites
255 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate whether a specific brain region mediates the cognitive deficit in long COVID brain fog, and whether targeted modulation of this region can improve cognition. In observational study, the objective was to identify potential intervention targets for patients with long COVID brain fog. A total of 120 patients with long COVID were enrolled. Brain fog (BF) severity was quantified using the Brain Fog Assessment (BFA). Participants completed a continuous random-dot motion (cRDM) task during 128-channel electroencephalography (EEG) and underwent structural MRI and standardized neuropsychological testing. In interventional study, 40 participants with persistent BF symptoms were enrolled for transcranial ultrasound stimulation (TUS). On Day 1, participants completed the BFA and provided demographic data, then performed the baseline cRDM task; 20 minutes later, structural MRI and baseline resting-state MRI were acquired. On Day 2, participants received 60 seconds of TUS (active or sham) according to randomized allocation. Twenty minutes post-stimulation, an 8-minute resting-state MRI scan was obtained, followed immediately by the follow-up cRDM task.
CONDITIONS
Official Title
Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of COVID-19 infection confirmed by positive PCR or rapid antigen test
- Persistent brain fog symptoms for at least 4 weeks after recovering from acute COVID-19
You will not qualify if you...
- Any cognitive impairment or neurological symptoms before COVID-19 infection
- Structural MRI showing significant brain lesions or abnormalities
- Severe neurological complications after COVID-19, including delirium, stroke, encephalitis, or epilepsy
- Other disorders causing cognitive impairment, such as dementia, schizophrenia spectrum disorders, stroke, Alzheimer's disease, or Parkinson's disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100053
Actively Recruiting
2
Shandong Daizhuang Hospital
Jining, Shandong, China
Actively Recruiting
Research Team
Y
Yi Tang, MD., PhD
CONTACT
S
Shaojiong Zhou, MD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here